Relapsed/Refractory Acute Myeloid Leukemia Market Growing Rapidly, Estimates DelveInsight | Key Companies Active in the Domain

DelveInsight’s analysts estimate that relapsed/refractory acute myeloid leukemia market is poised to show significant growth, mainly attributed to recent drug approvals, increasing incidence, and anticipated launch of novel therapies during the forecast period (2023–2032).

LAS VEGAS, May 24, 2023 /PRNewswire/ — DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, relapsed/refractory acute myeloid leukemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Market Report

• As per DelveInsight analysis, the relapsed/refractory acute myeloid leukemia market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• In 2020, 19,940 new cases and 11,180 deaths were estimated in the US according to Cancer Stat Facts. Despite advances in therapy, prognosis remains poor, with 28% alive at 5 years after diagnosis.
• Leading relapsed/refractory acute myeloid leukemia companies such as AROG Pharmaceuticals, Pfizer, Moleculin Biotech, Chordia Therapeutics, Inc., Theradex, CicloMed LLC, Amgen, Meryx, Inc., Merck Sharp & Dohme LLC, Cellectis S.A., Cullinan Oncology, LLC, Kite, Astellas Pharma Inc, Novartis, Cyclacel Pharmaceuticals, Inc., PureTech, AB Science, Cleave Therapeutics, Inc., Aptose Biosciences Inc., Kartos Therapeutics, Inc., Janssen Research & Development, LLC, Lava Therapeutics, and others are developing novel relapsed/refractory acute myeloid leukemia drugs that can be available in the relapsed/refractory acute myeloid leukemia market in the coming years.
• Some key therapies for relapsed/refractory acute myeloid leukemia treatment include Crenolanib, Annamycin liposomal, CTX-712, Fosciclopirox + Cytarabine, AMG 553, MRX-2843, Pembrolizumab, MK-0482, UCART123v1.2, CLN-049, KITE-222, ASP7517, VOB560 + MIK665, CYC065, LYT-200, AB8939, CB-5339, CG-806, KRT-232, JNJ-75276617, LAVA-051, and others.
• The emerging relapsed/refractory acute myeloid leukemia therapies are in their clinical trials’ mid and late phases and are awaiting a launch to make the pipeline robust.

Discover which therapies are expected to grab the major relapsed/refractory acute myeloid leukemia market share @ Relapsed/Refractory Acute Myeloid Leukemia Market Report

Relapsed/Refractory Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is a type of hematologic cancer that is distinguished by the clonal growth of myeloid blasts in the peripheral blood, bone marrow, and/or other organs. AML can affect tissues other than bone marrow and blood, such as lymph nodes, the brain, skin, and other organs. The majority of elderly people relapse or become refractory to early therapy. They are referred to as relapse/refractory AML patients. AML is the most frequent kind of acute leukemia in adults, primarily affecting the elderly, with a median age of diagnosis of 67 years. Each patient has a unique set of chromosomal abnormalities. A higher frequency of anomalies is connected with increasing age. AML and its subtypes are diagnosed via blood and bone marrow tests. The presence of a change in the number and appearance of blood cells aids in the R/R AML diagnosis.

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Segmentation

According to DelveInsight’s analysis, R/R acute myeloid leukemia is more prominent in males in comparison to females.

The R/R AML market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total R/R AML Incident Cases
• R/R AML Gender-specific Cases
• R/R AML Age-specific Cases
• R/R AML Mutation-specific Cases

Relapsed/Refractory Acute Myeloid Leukemia Treatment Market 

Most AML patients are treated with two chemotherapy phases: remission induction (also known as induction) and consolidation (postremission therapy). Allogeneic hematopoietic stem cell transplantation (HSCT) is the sole curative therapy option for the vast majority of R/R patients. Only patients who are physically fit enough to undertake the surgery are considered for HSCT. However, the majority of patients diagnosed with relapsed/refractory are elderly people with low performance scores, which limits therapy options. However, recent new medicine introductions aimed at R/R AML are attempting to meet this urgent need.

IDHIFA (enasidenib) was licensed by the US FDA in August 2017 to treat adult patients with relapsed or refractory AML who had the genetic mutation IDH2. The medicine is approved for use in conjunction with the RealTime IDH2 Assay, which detects particular mutations in the IDH2 gene in AML patients. IDHIFA is an orphan medication with priority review. The FDA approved TIBSOVO (ivosidenib) tablets in July 2018 for the treatment of adult patients with relapsed or refractory AML who carry the genetic mutation IDH1. This is the first medicine in its class (IDH1 inhibitors) to be licensed for use in conjunction with an FDA-approved companion test for detecting particular mutations in the IDH1 gene in AML patients. This drug has received fast-track and orphan classification for AML.

Moreover, the FDA approved XOSPATA (gilteritinib) tablets in November 2018 to treat adult patients with relapsed or refractory AML who have an FLT3 mutation as detected by an FDA-approved test. The FDA also approved an expanded indication for a companion diagnostic, allowing it to be used in conjunction with XOSPATA. Invivoscribe Technologies, Inc.’s LeukoStrat CDx FLT3 Mutation Assay is used to detect the FLT3 mutation in AML patients.

To know more about relapsed/refractory acute myeloid leukemia treatment, visit @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Drugs 

Key Relapsed/Refractory Acute Myeloid Leukemia Therapies and Companies

• Crenolanib: AROG Pharmaceuticals/Pfizer
• Annamycin liposomal: Moleculin Biotech
• CTX-712: Chordia Therapeutics, Inc./Theradex
• Fosciclopirox + Cytarabine: CicloMed LLC
• AMG 553: Amgen
• MRX-2843: Meryx, Inc.
• Pembrolizumab: Merck Sharp & Dohme LLC
• MK-0482: Merck Sharp & Dohme LLC
• UCART123v1.2: Cellectis S.A.
• CLN-049: Cullinan Oncology, LLC
• KITE-222: Kite
• ASP7517: Astellas Pharma Inc
• VOB560 + MIK665: Novartis
• CYC065: Cyclacel Pharmaceuticals, Inc.
• LYT-200: PureTech
• AB8939: AB Science
• CB-5339: Cleave Therapeutics, Inc.
• CG-806: Aptose Biosciences Inc.
• KRT-232: Kartos Therapeutics, Inc.
• JNJ-75276617: Janssen Research & Development, LLC
• LAVA-051: Lava Therapeutics

Learn more about the FDA-approved drugs for R/R AML @ Drugs for R/R AML Treatment 

Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics

The dynamics of the relapsed/refractory acute myeloid leukemia market are expected to change in the next years. The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the R/R AML market in the 7MM. Moreover, the pipeline for R/R AML is quite robust; many prospective therapies are being researched for relapsed/refractory acute myeloid leukemia treatment, and it is safe to expect that the relapsed/refractory acute myeloid leukemia treatment space will have a substantial impact on the relapsed/refractory acute myeloid leukemia market throughout the forecast period. 

However, several factors are impeding the growth of the relapsed/refractory acute myeloid leukemia market. Despite the new therapies, there are a number of constraints connected with the present medication environment. The older population’s overall survival rate remains relatively low. The presence of numerous chromosomal and genetic abnormalities makes treating R/R AML a difficult proposition, as the disease’s heterogeneity renders targeted therapies vulnerable. Many older people are unable to sustain the severe side effects of the aggressive chemotherapy therapies used to treat AML. These concerns necessitate the development of new treatments.

Moreover, the relapsed/refractory acute myeloid leukemia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the relapsed/refractory acute myeloid leukemia market growth.

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Market Report

• Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and emerging therapies
• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Attribute Analysis of Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Relapsed/Refractory Acute Myeloid Leukemia Market Access and Reimbursement

Discover more about relapsed/refractory acute myeloid leukemia drugs in development @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

Table of Contents

Related Reports

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted relapsed/refractory acute myeloid leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Relapsed/Refractory Acute Myeloid Leukemia Pipeline

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsed/refractory acute myeloid leukemia companies, including Maxinovel Pty., Ltd., Cellectis S.A., Amgen, Ascentage Pharma, Shijiazhuang Yiling Pharmaceutical, CicloMed LLC, AB Science, Betta Pharmaceuticals Co., Ltd., Chongqing Precision Biotech Co., Ltd, Astellas Pharma, Keystone Nano, Cullinan Oncology, LLC, Arog Pharmaceuticals, Inc., among others.

Acute Myeloid Leukemia Pipeline

Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Lymphocytic Leukemia Pipeline

Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP